{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:22:28Z","timestamp":1772310148583,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0148539","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T18:52:29Z","timestamp":1454698349000},"page":"e0148539","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia"],"prefix":"10.1371","volume":"11","author":[{"given":"Mong-Liang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ting","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: A concise overview of incidence, prevalence, and mortality","volume":"30","author":"J McGrath","year":"2008","journal-title":"Epidemiol Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"JA Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"A Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2009.05.030","article-title":"Effectiveness of second-generation antipsychotics with acute-phase schizophrenia","volume":"113","author":"K Hatta","year":"2009","journal-title":"Schizophr Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4236\/ojpsych.2015.53034","article-title":"Differences in baseline characteristics of patients treated with olanzapine or other antipsychotics in japanese patients with acute schizophrenia: A 1-year observational study under routine clinical practice in japan","volume":"5","author":"M Takahashi","year":"2015","journal-title":"Open J Psychiatry"},{"key":"ref6","first-page":"CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"K Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","first-page":"281","article-title":"Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses","volume":"53","author":"B Fulton","year":"1997","journal-title":"Drugs"},{"key":"ref8","first-page":"749","article-title":"Olanzapine approved for the acute treatment of schizophrenia or manic\/mixed episodes associated with bipolar i disorder in adolescent patients","volume":"6","author":"AE Maloney","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e31828b28d5","article-title":"Olanzapine: A systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response","volume":"33","author":"D Bishara","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"ref10","first-page":"177","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"JT Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref11","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"K Kassahun","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"KL Bigos","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eurpsy.2004.09.009","article-title":"Clinical outcome and olanzapine plasma levels in acute schizophrenia","volume":"20","author":"MC Mauri","year":"2005","journal-title":"Eur Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: Acute phase results of the north american olanzapine trial","volume":"21","author":"PJ Perry","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo university schizophrenia projects (jusp)","volume":"30","author":"M Nozawa","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"Agnp consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011","volume":"44","author":"C Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00004714-199712000-00006","article-title":"Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients","volume":"17","author":"PJ Perry","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","article-title":"The Maudsley Prescribing Guidelines","author":"D Taylor","year":"2009"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its n-demethyl metabolite in the naturalistic clinical setting","volume":"24","author":"E Skogh","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication","volume":"25","author":"M Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e65719","DOI":"10.1371\/journal.pone.0065719","article-title":"Determination of olanzapine and n-desmethyl-olanzapine in plasma using a reversed-phase hplc coupled with coulochemical detection: Correlation of olanzapine or n-desmethyl-olanzapine concentration with metabolic parameters","volume":"8","author":"ML Lu","year":"2013","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (panss) for schizophrenia","volume":"13","author":"SR Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the panss mean?","volume":"79","author":"S Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-244X-7-35","article-title":"Statistical validation of the criteria for symptom remission in schizophrenia: Preliminary findings","volume":"7","author":"MGA Opler","year":"2007","journal-title":"BMC psychiatry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Y Benjamini","year":"2001","journal-title":"Ann Stat"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/JCP.0b013e318204d9e2","article-title":"High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug","volume":"31","author":"E Skogh","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00007691-200312000-00006","article-title":"Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia","volume":"25","author":"L Fellows","year":"2003","journal-title":"Ther Drug Monit"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg\/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"L Citrome","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.jcp.0000185427.08268.db","article-title":"Effects of age and sex on olanzapine plasma concentrations","volume":"25","author":"U Weiss","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.pnpbp.2008.08.022","article-title":"Pharmacokinetics of olanzapine in chinese male schizophrenic patients with various smoking behaviors","volume":"32","author":"TH Wu","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its n-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: Effects of dose, diagnosis, age, sex, smoking, and comedication","volume":"28","author":"FM Theisen","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref32","first-page":"23","article-title":"Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics","volume":"10","author":"A Wakamatsu","year":"2013","journal-title":"Innov Clin Neurosci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0148539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:10:39Z","timestamp":1654261839000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0148539"}},"subtitle":[],"editor":[{"given":"Peter John","family":"McKenna","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0148539","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]}}}